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Background: Despite positive reports on the efficacy of stem cell therapy for the treatment of cardiovascular
disease, the nature of stem cell homing to ischemic tissues remains elusive.
Results: We used a mouse model of peripheral tissue ischemia to study the survival and homing capacity of dual
reporter gene (eGFP/Luciferase) expressing bone marrow-derived stromal cells (BMSC). Cell homing and survival
were studied in the presence and absence of ciclosporin A (CsA) immunosuppression using bioluminescence
imaging (BLI) together with confocal endomicroscopy. Different injection strategies were applied: central venous
(CV), intra-arterial (IA) and intramuscular (IM). BLI and confocal endomicroscopy evidenced complete rejection of the
IM injected allogeneic BMSC transplant within 5 to 10 days. Immunosuppression with CsA could only marginally
prolong graft survival. IM injected BMSC did not migrate to the site of the arterial ligation. CV injection of BMSC
resulted in massive pulmonary infarction, leading to respiratory failure and death. Intrapulmonary cell trapping was
evidenced by confocal endomicroscopy, BLI and fluorescence microscopy. IA injection of BMSC proved to be a
feasible and safe strategy to bypass the lung circulation. During the follow-up period, neither BLI nor confocal
endomicroscopy revealed any convincing ischemia-directed homing of BMSC.
Conclusions: BLI and confocal endomicroscopy are complementary imaging techniques for studying the in vivo
biology of dual reporter gene-expressing BMSC. Allogeneic BMSC survival is limited in an immunocompetent host
and cannot be preserved by CsA immunosuppression alone. We did not find substantial evidence for
ischemia-directed BMSC homing and caution against CV injection of BMSC, which can lead to massive pulmonary
infarction.
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Mesenchymal stem cell (MSC) therapy is currently being
explored in almost any clinical field involving tissue res-
toration or modulation of immune responses [1]. This
widely applicable, simple and straightforward therapy
would represent a milestone in modern medicine. The* Correspondence: berteveraert@me.com
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reproduction in any medium, provided the orinitial enthusiasm about the promising results of MSC
therapy in preclinical animal studies, and later on also in
phase 1 and phase 2 clinical trials was subsequently
tempered by the outcome of larger randomized,
placebo-controlled trials. The reasons herefore are not
completely understood and probably relate to our lack
of knowledge and understanding of the complex nature
of MSC biology.
MSC were first described as clonogenic fibroblast pre-
cursor cells, residing in mouse bone marrow, thymus and
spleen [2]. After 30 years of MSC research, the Internationall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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exchange between investigators, came up with a set of
minimal criteria to define human MSC. These cells
should be plastic-adherent when maintained in standard
culture conditions, have multilineage differentiation po-
tential into osteoblasts, adipocytes and chondroblasts
in vitro and express a specific set of cellular markers.
Despite the consensus on in vitro MSC characteris-
tics, many unresolved questions remain about MSC
biology in vivo, precluding its potential clinical applic-
ability on a large scale [1,3]. Key questions on whether
MSC truly undergo lineage differentiation and on the
mechanisms through which these cells act on target
tissues, i.e., their anti-apoptotic, pro-angiogenic or im-
mune modulatory properties, are still matter of intense
debate. Although many animal studies reported the posi-
tive effects of MSC therapy, usually very little informa-
tion is provided about the long-term survival and
engraftment of the administered MSC. A plausible ex-
planation for this lack of information might be the ab-
sence of an easily applicable “gold standard” for studying
cell survival and homing in vivo. Indeed, whole-body im-
aging techniques using radioactive or magnetic labeling
dyes, fluorescent markers or reporter genes, all have dis-
advantages and probably a combination of different im-
aging modalities is needed to provide a reliable picture.
In addition, uncertainty remains about the optimal
transplantation route, time frame and cell dose, and
whether homing after systemic infusion is an active ra-
ther than passive “cell entrapment” phenomenon [4,5].
Finally, the safety of injecting vast amounts of foreign
cells is a matter of concern, and although a relatively
large amount of safety data has been gathered from
phase 1 and 2 clinical trials, the observation that many
systemically infused MSC become entrapped in the
lungs warrants further investigation [6].
In the present study we combined two complementary
in vivo imaging techniques, i.e., bioluminescence imagingFigure 1 Baseline expression of reporter genes before BMSC cell inje
bioluminescence imaging. 2: In vivo endomicroscopy images of eGFP expre(BLI) and confocal endomicroscopy, to study dual re-
porter gene-expressing stem cell suvival and migration
towards an ischemic stimulus in vivo.Results
Survival and migration characteristics of locally injected
BMSC
To study the in vivo survival and migration characteris-
tics of IM injected BMSC, cells were transplanted into
the calf muscles 24 h after induction of hindlimb ische-
mia. Prior to injection, eGFP fluorescence intensity and
Luciferase activity were checked by confocal endomicro-
scopy and bioluminescence imaging methods, respect-
ively (Figure 1). Mean (±SD) cell diameter was 13.4μm
(±3.5). The biology of the cell transplant was investi-
gated during a 3-week follow-up period using both
in vivo imaging techniques. The high optical resolution
(micrometer scale) of confocal endomicroscopy enabled
us to perform a detailed study of the survival and differ-
entiation characteristics of single cells in the BMSC
transplant and to monitor BMSC homing towards the is-
chemic site. BMSC could be seen as a sharp delineated
tissue infiltrate at baseline. The transplanted cells devel-
oped a spindle-shaped pattern with cell branches within
a few days. The transplant appeared to be stable
throughout the first week but then displayed a rapid and
steep drop in BMSC number and density during the sec-
ond week. As a result of the rejection of the BMSC
transplant, cellular morphology became more heteroge-
neous in both size and appearance, less densely orga-
nized and more fragmented. BLI signals were in
accordance with endomicroscopic findings (Figure 2).
Signal intensity and position of the cell transplant
remained fairly stable in the first week after transplant-
ation. Hereafter, BLI signals rapidly faded to background
levels in all animals during the second week after trans-
plantation. Using BLI to discern active homing of thection. 1: Luciferase expression of BMSC measured with
ssing BMSC before injection.
Figure 2 Survival of IM injected BMSC visualized with bioluminescence (upper row) versus confocal endomicroscopy (lower row).
Immediately after IM injection a cell infiltrate was seen at the injection site. In the absence of immunosuppression, in most animals no residual
cells were detectable beyond 8 days after cell transplantation. BMSC survival in mice treated with CsA was only temporarily prolonged. At day 8
post-transplantation some residual, viable cells were still observed, but the signal weakened rapidly during the second week after transplantation.
No cell infiltrate was detected beyond 10 days after transplantation.
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what difficult because of the low optical resolution
(± 1mm) of the BLI technique), we did not observe
much change in the position of the cell transplant over
time, nor was there evidence for active homing towards
the ischemic site. To study the homing capacity of indi-
vidual BMSC, we applied confocal endomicroscopy to
the site of tissue ischemia. Here, the day after transplant-
ation, only one eGFP positive cell could be found in the
ischemic muscular region in only one transplanted ani-
mal. However, at all later time points, confocal endomi-
croscopy did not demonstrate homing of eGFP+ BMSC
towards the area surrounding the ligation site Table 1.Ciclosporin immune suppression cannot sustain
prolonged BMSC survival
To study whether BMSC rejection could be delayed, we
studied the rejection process of IM injected BMSC in ani-
mals treated with or without daily IP injections of CsA
(n=8 for both groups). Using BLI and confocal endomicro-
scopy, we were able to show that this immunosuppres-
sive regimen only marginally prolonged BMSC transplantTable 1 Comparison of detection techniques
Bioluminescence imaging Confocal endomicroscopy
Strength Non-invasive High spatial resolution













Superior specificity Superior spatial resolutionsurvival, a difference that was not statistically significant
(p=0.14) (Figure 3). To exclude the possibility of underim-
munosuppression, a higher dose of CsA (30mg/kg/d in-
stead of 10mg/kg/d) was used in about half of the animals.
No apparent difference in BMSC transplant survival was
observed between mice treated with either high- or low-
dose immunosuppression.
Intrapulmonary cell trapping of BMSC
CV injection of BMSC by right heart cannulation resulted
in respiratory distress and led to respiratory failure and
death within minutes (5/5). Confocal endomicroscopy on
resection specimens revealed trapped eGFP+ BMSC in
both lungs, the right ventricle and the right atrium. Intra-
pulmonary cell trapping was confirmed by BLI imaging
30 min after injection of D-luciferin pre-incubated BMSC.
Bioluminescence signals were clearly visible in both lungs
and were restricted to the right side of the heart. No BLI
signal could be detected in the left atrium or the left ven-
tricle, nor in tissue specimens of liver, kidney, spleen orFigure 3 BMSC transplant survival evidenced by
BLI/endomicroscopy in IM injected animals treated with
or without CsA.
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BMSC injection was further evident on fluorescence
microscopic images of formalin-fixed, paraffin-embedded
lung slices. eGFP+ cells were seen in small vessels or ca-
pillaries throughout the entire lung (Figure 5). Some cells
appeared as round cells, while others displayed cell pro-
cesses and seemed to evade the pulmonary circulation
and enter into the lung parenchyma.
Minimal evidence for BMSC homing after systemic
transplantation
To study the process of ischemia-directed cell homing,
BMSC were injected directly into the arterial circulation
(n=5) by direct injection into the left heart ventricle, as
such bypassing the pulmonary circulation. This procedure
proved to be feasible and safe. During a two-week follow-
up period, neither BLI nor confocal endomicroscopy
demonstrated any convincing sign of active migration
of BMSC towards the ischemic site in an immunocompe-
tent host (n=2). However, in one out of three animals
treated with CsA (10mg/kg/d), a cluster of three BMSC
was detected by confocal endomicroscopy in the same
microscopic plain of the ischemic hindlimb (Figure 6,
video sequence provided as Additional file 1). Taking into1 2
54
87
Figure 4 BLI imaging of dissection specimens 30 min after CV injectio
entire lung (3 independent experiments) and in the right heart ventricle (lo
septum). Note that the left ventricle is devoid of luminescent cells. 6–9: No
spleen (8); kidneys (9)).account their typical morphology, size and fluorescence
intensity, we feel confident that these cells are indeed
living BMSC. Whether these cells actively migrated to
the ischemic site or whether their presence was merely a
chance phenomenon due to passive cell entrapment, is
impossible to deduce from this limited amount of study
data. This small number of detected cells, together with
the scarce evidence for BMSC homing in IM transplant-
ation experiments, led us to conclude that active BMSC
homing is a rare event.
Discussion and conclusions
In this study we investigated BMSC survival and
ischemia-directed homing using two in vivo reporter gene
expression imaging techniques, BLI and confocal endomi-
croscopy. Endomicroscopy has superior sensitivity in
visualizing transplants at low cellular concentrations or
with fading tracer signals. Its high optical resolution
enables the study of cellular morphology, delineation of
the cell infiltrate as well as homing capacity of individual
cells. Drawbacks of the technique are its invasive nature
requiring direct tissue contact with limited deep tissue
penetration. Autofluorescence did occur at times but the
chance of false positive findings in our study was rather3
6
9
n of BMSC. 1–5: Bioluminescent BMSC are present throughout the
ngitudinal (4) and cross-section (5), red bar depicts the interventricular
signals are observed in the blood (6), or in other organs (liver (7);
21
43
Figure 5 Lung entrapment of BMSC. 1–3: Fluorescence microscopic images of lung slices show eGFP+ BMSC as microemboli throughout the
entire lung. Cells and cell aggregates can be seen in vascular structures (10×). 4: Higher magnification of image 3. Intravascular cell entrapment
and diapedesis into the lung parenchyma (red arrowhead) of CV injected BMSC (40×).
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BMSC. BLI, on the other hand, is a non-invasive and
hence more practical technique to use in follow-up stud-
ies of transplant survival, but it lacks the high optical
resolution of endomicroscopy. It also has superior specifi-
city for detecting Luc+ cells. However, BLI is unable to
detect single cells or transplants with low cell concentra-
tion or limited cell numbers. Nevertheless, a combination
of the high specificity of BLI joined with the high optical
resolution of confocal endomicroscopy, overcomes several
constraints of either technique alone and enables to studyFigure 6 Ischemia-directed homing of BMSC after intra-arterial injecti
site. Of note are the typical BMSC cell size, cellular morphology and eGFP+the biology of BMSC survival and homing with more pre-
cision and accuracy.
Studying cell homing using reporter genes has several
advantages over conventional cell tracking agents, such
as cell labeling dyes, microparticles, radioisotopes or
magnetic resonance imaging (MRI) contrast agents. An
important drawback of these conventional methods is
that the agent used can become decoupled from the ori-
ginal cell transplant and/or ingested by other cell types,
such as macrophages. Macrophage ingestion is a major
confounder in transplantation studies because manyon. Confocal endomicroscopic image of three BMSC at the ischemic
fluorescence indicating living cells.
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triggering a local immune reaction with macrophage in-
filtration [7].
Because reporter genes are integrated into the cell
genome, cell tracking studies using reporter gene expres-
sion is much less likely to yield false positive results: the
expression of the reporter gene is limited to viable cells
of the original cell transplant and is preserved in succes-
sive cell divisions. When cells do not survive or are
ingested by other cells, the signal diminishs over time.
However, since the reporter gene is integrated in the
genomic DNA, cell proliferation will increase rather
than decrease signal intensity [4], as such preventing di-
lution of the original labeling signal.
Despite these benefits, the use of reporter genes also
entails a number of caveats. A first problem could arise
from the induction of immune responses directed against
non-host alloantigens expressed on the cell surface of the
transfected cells that express non-self proteins, such as
Luc or eGFP. However, Bergwerf et al. [8] demonstrated
that the immune reactive cytotoxic T-cell response fol-
lowing BMSC transplantation was not specific for the
non-self eGFP or Luc genes. These authors suggested that
the observed T-cell mediated transplant rejection could
be due to the presence of xenogeneic constituents of the
growth medium, such as fetal calf and horse serum,
which render the cultured cells more immunogeneic. An-
other concern is gene silencing, which is a mechanistically
very complex phenomenon that can vary with specific ex-
perimental conditions due to a site-dependent adaptation
of the expression of the reporter gene in vivo [9].
We demonstrated in our hindlimb ischemia mouse
model that cell transplant survival after IM injection was
limited in time and that CsA immunosuppression alone
was not sufficient to maintain long-term survival of the
allogenic BMSC graft. Our data are in line with the BLI
results of Swijnenburg et al [10]. In this study, immuno-
suppression with mycophenolate mofetil, sirolimus or
tacrolimus, both in monotherapy or in combination,
failed to induce long-term survival of embryonic stem
cell xenografts. On the other hand, Swanger et al. [11]
showed that, at least in the central nervous system, high
dose CsA significantly increased allogeneic BMSC graft
survival compared to standard dose CsA, indicating that
higher doses of CsA could be sufficient to maintain
long-term survival of allogeneic BMSC at immunologic-
ally privileged sites. Furthermore, evidence from BLI
experiments from Zangi et al. [12] about survival and re-
jection of IV or intraperitoneally injected allogeneic
MSC transplants, indeed showed that, at least in mice,
survival of a systemically injected MSC transplant is lim-
ited in time. Moreover, it was demonstrated that even
IM injection of BMSC in immune competent syngeneic
mice did not result in permanent graft survival [8].We used a hindlimb ischemia model for the study of
ischemia-directed homing firstly for reasons of good ac-
cessibility of the tissues of interest for the optical probe
of the confocal endomicroscope. Therefore, in vivo
endomicroscopy would be less suitable to study homing
towards deeper anatomical structures or to moving
organs, such as the heart. Secondly, hindlimb ischemia
mouse models have already been validated extensively as
experimental set-up for the study of ischemia-directed
MSC homing. A better understanding of survival and
homing characteristics of MSC in this experimental
model is of particular relevance for the early-phase clin-
ical trials on the use of human MSC for the treatment of
critical limb ischemia that are currently ongoing [13].
We caution against CV injection of large amounts of
BMSC because this leads to massive pulmonary infarc-
tion. Gao and co-workers already reported that systemic
injection of MSC initially results in retention in the
lungs, after which a gradual redistribution could be seen
to the liver, bone marrow and other organs. These
authors showed that the pulmonary retention could be
reduced using the vasodilator sodium nitroprusside [14].
This finding, i.e. initial intrapulmonary cell trapping with
gradual tissue redistribution, was confirmed by Daldrup-
Link et al. [15], who used MRI imaging, and by in vivo
BLI studies by Schrepfer et al. [16]. In the latter study,
episodes of tachypnea, apnea and hemodynamic altera-
tions, characteristic of pulmonary embolism, were
reported when MSC were directly infused into the infer-
ior vena cava. Pulmonary entrapment was also evident
in a myocardial infarction study with BrdU-labeled MSC
[6]. When the lung circulation was bypassed through
direct intracavitary administration of MSC, significantly
more cells were observed within the infarction zone
within the first hours after transplantation. In a later re-
port by the same authors, long-term engraftment of the
infused MSC, as initially suggested on the MRI images,
could not be verified with Y chromosome gene detection.
Further analysis revealed that the positive MRI signals
originated from cardiac resident macrophages that had
ingested the MRI contrast particles. Intriguingly, al-
though cells of donor origin were absent at 4 weeks after
infusion, ventricular function was still improved in the
MSC-treated animals [17]. The authors attributed this
phenomenon to possible paracrine effects. Another tis-
sue distribution study in the clinical setting of myocar-
dial infarction, showed initial lung uptake of intravenous
(IV) injected 18F-FDG-labeled bone marrow-derived
cells, followed by a gradual redistribution to the reticulo-
endothelial system (spleen, liver, bone marrow) [18].
Stem cell homing towards the infarction site, however,
could not be demonstrated. Evidence for the pulmonary
entrapment of stem cells was also reported after IV
injection of neural stem cells [19], leading to massive
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studies indicate that the lung might act as a barrier for
the passage of different stem cell subtypes [20], especially
for those that are relatively large and express abundant
adhesion molecules [21]. Our study adds further evi-
dence to the finding of intrapulmonary cell trapping after
CV injection of BMSC and questions the safety of this
route for BMSC transplantation.
As indicated by our results, direct intracavitary injec-
tion into the left ventricle is a feasible approach to cir-
cumvent this pulmonary “first-pass” effect, but it is
rather impractical to use in small animal experiments.
However, direct IA administration of BMSC in the arter-
ial circulation, e.g. by intracoronary injection after myo-
cardial infarction, thereby avoiding the lung circulation,
would in our opinion prove to be the method of choice
for BMSC cell application in large animal and human
clinical trials. Furthermore, considering that active
ischemia-directed BMSC homing of unstimulated BMSC
was a rare biological phenomenon in our studies, this
also favours direct IA injection of BMSC into the vascu-
lature of the tissue of interest. Alternatively, the homing
process could potentially be improved with use of stimu-
lated rather than naive BMSC. BMSCs can easily be
ex vivo manipulated by pretreatment, preconditioning
and genetic modification, which was reported to increase
their therapeutic benefit [22]. For instance, hypoxic pro-
conditioning has been shown to stimulate the induction
of several chemokine receptors, such as CXCR4 and
CXCR7. This led to improved migration and recruitment
of BMSC into ischemic tissues and stimulated secretion
of proangiogenic and mitogenic factors improving thera-
peutic potential of the transplanted BMSC [23].
As a limitation of our work, we are aware that we
could have underestimated the BMSC homing process
because of the specific limitations of our detection tech-
niques and experimental set-up. However, by combining
the advantages of BLI with endomicroscopy, we feel
confident about our results. However, it is possible that
we underestimated the homing potential of BMSC, be-
cause of the limited graft survival time or the use of
naive rather than stimulated or manipulated BMSC.
Also, the use of CsA could have interfered with BMSC
kinetics or altered the BMSC microenvironment, leading
to an impaired homing respons. Transgenic immuno-
deficiency models, rather than immunosuppression with
pharmacological agents, would be an interesting alterna-
tive to use in future studies on BMSC survival and hom-
ing. Finally, increasing the number of observations in
each group would further strengthen our statements.
In summary, in this study a combination of BLI and
confocal endomicroscopy was applied for dual reporter
gene-expression imaging of BMSC survival and homing
in a clinically relevant mouse model of peripheral tissueischemia. We report that allogeneic BMSC graft survival
time was limited in the ischemic muscle and that CsA
immunosuppression alone was not able to sustain long-
term survival of the allograft. We did not find abundant
evidence for ischemia-directed BMSC homing as a com-
mon biological process and caution against the direct
CV injection of large amounts of BMSC.
Methods
Animals
Homozygous ROSA26-L-S-L-Luciferase transgenic mice
(FVB background) were purchased from Jackson Labora-
tories (strain 005125) and further bred in the specific
pathogen-free animal facility of the University of Ant-
werp. Male offspring was used for BMSC culture. Male
C57Bl/6 mice (Charles River) (n=26) were used as
acceptors. Animals were kept in a normal day-night
cycle (12/12) with free access to food and water. Na-
tional and European principles of laboratory animal care
were followed. All animal experimental procedures were
approved by the Animal Care and Use Committee of the
University of Antwerp (Permit Number: 2008–03).
Reporter gene-expressing bone marrow-derived stromal
cells (BMSC)
BMSC genetically engineered with the Luciferase (Luc)
and enhanced Green Fluorescent Protein (eGFP) reporter
proteins were cultured and phenotypically characterized
as previously described by Bergwerf et al. [8]. eGFP+/Luc+
BMSC were cultured in “complete expansion medium”
(CEM) consisting of Iscove’s modified Dulbecco’s medium
(Cambrex) supplemented with 8% fetal bovine serum
(HyClone Laboratories), 8% horse serum (Invitrogen),
100 U/mL penicillin (Invitrogen), 100 mg/mL strepto-
mycin (Invitrogen), 0.25 mg/mL amphotericin B (Invitro-
gen). CEM was supplemented with 1 μg/mL Puromycine
(Invivogen) to induce eGFP expression (eGFP-IRES-Pac
cassette). Cultures were harvested twice a week using
trypsin-EDTA (Invitrogen) and passaged at a 1:3 ratio in
15ml CEM in T75 culture flasks. Cells of passage number
5 to 20 were used in the experiments. Before transplant-
ation, eGFP+/Luc+ BMSC were washed twice in sterile
PBS solution and resuspended at a final concentration of
5.106 BMSC/ml NaCl 0,9%. Cell preparations were kept
on ice until cell injection.
Hindlimb ischemia mouse model and cell transplantation
Hindlimb ischemia was induced by ligation of the left
femoral artery (LFA). In brief, 3- to 5-month-old male
C57BL/6 mice were anesthetized (demetomidine 0.4ml/kg
and ketamine 37.5mg/kg, intraperitoneally). The LFA was
ligated as close as possible to the left inguinal ligament
using 7–0 polypropylene sutures (ProleneW, Ethicon,
Johnson & Johnson). Subsequently, the operation wound
Everaert et al. BMC Biotechnology 2012, 12:93 Page 8 of 9
http://www.biomedcentral.com/1472-6750/12/93was closed and animals were placed under a heat source
until full recovery. After 24h, mice were re-anesthetized
and transplanted with 500.103 eGFP+/Luc+ BMSC dis-
solved in 0.1ml NaCl 0.9%. The transplant route was ei-
ther central venously (CV) by right heart cannulation
(n=5), intra-arterial (IA) by left ventricular cannulation
(n=5) or intramuscular (IM) directly into the calf muscle
(n=16). For right and left heart cannulation, animals were
intubated (23G catheter) and mechanically ventilated
(10μl/g, 180/min, 2cm H2O positive end-expiratory pres-
sure) and a small parasternal thoracotomy was performed.
Systemic injection was performed slowly at a rate of
100μl/min. To study the effects of the presence or ab-
sence of immunosuppressive therapy on immune rejec-
tion of the cell transplants, animals were treated with
(n=13) or without (n=13) daily intraperitoneal injection of
CsA. Two dosage regimens were compared: 10mg/kg/d
(n=6) versus 30mg/kg/d (n=7).
Confocal endomicroscopy
Homing of eGFP+/Luc+ BMSC was visualized in vivo
with the CellvizioW LAB system (Mauna Kea Technolo-
gies) equipped with a 488nm excitation laser. CellvizioW
LAB is a high-speed fluorescence microscope that per-
mits real-time endoscopic fluorescence imaging through
high-resolution fiber bundle micro-optics (UltraMini0
microprobe: tip diameter 2.6mm, lateral resolution
1.4μm, field of view 240μm, working distance 60μm). In
each mouse, cell homing was visualized 3 times per
week, for a time period of 3 weeks. In brief, mice were
anesthetized (demetomidine 0.4ml/kg and ketamine
37.5mg/kg, intraperitoneally). A small skin incision was
made in the inguinal region, the microprobe was
advanced towards the ligation site and the underlying
muscular tissues were scanned for the presence of fluor-
escent cells. A second incision at the level of the calf
muscles enabled us to study the morphology, survival
and homing characteristics of the IM injected cell infil-
trate distal to the ligation site. Tissues were imaged for
at least 5 min with continuous video recording. The
contralateral hindlimb served as a negative control to
discriminate eGFP+ cell homing from autofluorescence
background signals. After the procedure, the operation
wounds were closed using 7–0 polypropylene sutures
(ProleneW, Ethicon, Johnson & Johnson).
In vivo bioluminescence imaging (BLI)
In all transplanted mice, homing of viable eGFP+/Luc+
BMSC was analyzed with a non-invasive in vivo photon-
imager system (Biospace), three times weekly for 3
weeks (or less in case BLI signals consistently disap-
peared earlier). Mice were anesthetized (demetomidine
0.4ml/kg and ketamine 37.5mg/kg, intraperitoneally)
and intraperitoneally injected with 100μl D-luciferin(30mg/ml, dissolved in PBS) with a 29G needle. After
10 min, bioluminescence signals were recorded for at
least 10 min. Bioluminescence recordings were layered
onto a visual photographic image to create composite
bioluminescence - photographic images. The data were
analysed with Photovision software. To study the pheno-
menon of intrapulmonary cell trapping, CV injected
BMSC were pre-incubated with D-Luciferin. Biolumines-
cence images of the dissected lungs, heart, spleen, kidneys,
liver and blood were obtained postmortem.
Histology – fluorescence microscopy
Tissue specimens were fixed in 4% paraformaldehyde for
2 h at room temperature, washed 3 times with PBS and
stored overnight in 70% ethanol. Tissues were paraffin-
embedded, sliced into 5μm thick tissue sections and ana-
lyzed for eGFP+ cells using a Zeiss Axiophot fluores-
cence microscope equipped with an DP70 digital camera
system (Olympus). Images were analyzed in CellP Im-
aging Software version 3.4 (Olympus).
Statistical analysis
Logrank test was used for curve comparison of survival
data. A p-value of <0.05 was considered to be statistically
significant.
Additional file
Additional file 1: BMSC cluster.
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